- Type 2 DM:
- PO 2.5-5mg OD
- Max 5mg
- Tablet:
- 2.5mg
- 5mg
- May need to reduce dosage of sulfonylurea or other insulin secretagogues when administered in combination
- Taken without regards to food
DPP-4 Inhibitor antidiabetic
It inhibits dipeptidyl peptidase-4, slowing incretin metabolism, increasing insulin synthesis/release and decreasing glucagon levels
- URI
- UTI
- Headache
- Hypoglycemia
- Vomiting
- Peripheral edema
- Abdominal pain
- Renal impairment
- Gastroenteritis
- Hypersensitivity reaction
- Hypersensitivity to class/components
- Type I DM
- Diabetic ketoacidosis
None restricted
Drug Status
| Availability | Prescription only |
| Pregnancy | Weigh risk vs benefit |
| Breastfeeding | Not recommended |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Onglyza | 5mg | Tablet | 30’s | AstraZeneca | AstraZeneca |
| Onglyza | 2.5mg | Tablet | 30’s | AstraZeneca | AstraZeneca |